+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease



Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease



Journal of Clinical Lipidology 11(6): 1441-1447



Among high-risk individuals, statins are beneficial for primary prevention of cardiovascular disease (CVD). In Nigeria, currently, there are no CVD prevention guidelines, so the use of CVD risk estimation to guide statin therapy is left to the discretion of the physician. The objective of the study was to compare 3 CVD risk estimation tools in the evaluation of patients presenting to a tertiary hospital in Nigeria. Cross-sectional study involving 295 patients with any CVD risk factors but not taking statins. Traditional CVD risk factors were assessed with a standard questionnaire and laboratory evaluation. Ten-year CVD risk was estimated with American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease (ACC/AHA ASCVD) Risk Estimator (2013), Framingham Risk Score (Framingham Risk Score [FRS] 2008), and the World Health Organisation/International Society of Hypertension (WHO/ISH) risk prediction chart for Africa Region D. Kappa statistic was used to determine agreement among the estimators. The mean age was 48.4 ± 10.4 years; 60.7% were females. Risk factors for CVD were hypertension (56.3%), dyslipidemia (41.4%), diabetes (20%), obesity (28.5%), and cigarette smoking (4.4%). In all, 50.2%, 16.9%, and 15.2% were classified as high risk using the ACC/AHA ASCVD Risk Estimator, FRS 2008, and WHO/ISH risk chart, respectively. The agreement was moderate between FRS and WHO/ISH (Kappa 0.414, P < .001) and fair between ACC/AHA Estimator and WHO/ISH (Kappa 0.223, P < .001) and between ACC/AHA Estimator and FRS (Kappa 0.301, P < .001). The considerable variation in prediction of high risk using the 3 tools may lead to underutilization of evidence-based therapy. This underscores the dire need for the development of risk prediction tools derived from our own Nigerian population.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059527431

Download citation: RISBibTeXText

PMID: 29050979

DOI: 10.1016/j.jacl.2017.09.004


Related references

Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA 314(2): 142-150, 2015

Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England. Bmj Open 5(3): E007207, 2015

Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis. Circulation. Cardiovascular Quality and Outcomes 11(4): E004171, 2018

Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. Indian Journal of Medical Research 138(4): 461-491, 2015

Initiation of statin therapy for the primary prevention of CHD based on modifiable or absolute risk?. American Journal of Hypertension 16(5 Part 2): 161A, 2003

Statin therapy for primary prevention of cardiovascular disease. JAMA 310(22): 2451-2452, 2013

Predictors of residual cardiovascular risk in patients on statin therapy for primary prevention. Cardiology 119(4): 187-190, 2012

Statin Therapy: Diabetes Mellitus Risk and Cardiovascular Benefit in Primary Prevention. Israel Medical Association Journal 20(8): 480-485, 2018

Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. Clinical Cardiology 28(7): 317-320, 2005

Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients. Current Atherosclerosis Reports 21(8): 28, 2019

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Therapeutic Advances in Cardiovascular Disease 3(4): 309-315, 2009

Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. Circulation 133(16): 1574-1581, 2016

Assessment of Cardiovascular Risk and Statin Utilization for Primary Prevention in Patients with Non Alcoholic Fatty Liver Disease (NAFLD). Gastroenterology 152(5): S1203-S1204, 2017

Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention. Evidence-Based Medicine 20(6): 230, 2016

Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy. Journal of the American College of Cardiology 66(24): 2699-2709, 2016